Canopy Growth (CGC) surged 18% after Trump praised CBD for senior health. Stock up 100% YTD. Potential reclassification could boost CGC, opening U.S. market. Legitimizing cannabis would increase demand. Expansion via Acreage Holdings could accelerate. But caution: steep losses, debt, limited U.S. exposure, speculative federal reform. Long-term growth needed.

Wall Street bullish on Canopy Growth despite risks. Consensus “Hold” rating, $2.38 target implies 50% upside. Trump’s CBD endorsement could be game-changer. Momentum traders may jump in, but long-term investors should be cautious. CGC’s future hinges on revenue growth, margin improvement, and financial discipline.

Read more at Yahoo Finance: As Trump Promotes CBD, Should You Buy, Sell, or Hold Canopy Growth Stock?